Moreover, the CB2R agonist, PF [99], has been shown to exert an anti-neuroinflammatory effect in VaD rats, by significantly inhibiting CCH-induced mammalian target of mTORC1/ NF-κB pro-inflammatory pathway signaling and enhancing phosphatidylinositol-3 kinase (PI3K)/ protein kinase B (AKT/PKB) anti-inflammatory pathway signaling [99] (Fig. 2). Here, AKT1 is linked to columnar cell hyperplasia of the breast.